XML 87 R75.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2023
USD ($)
Schedule of Activity in Contingent Consideration [Roll Forward]  
Balance at beginning of period $ 375.0
Payments 9.7
Reclassifications 0.0
Accretion expense 5.7
Fair value loss 1.5
Balance at end of period 372.5
Biocon Biologics  
Schedule of Activity in Contingent Consideration [Roll Forward]  
Balance at beginning of period 221.2
Balance at end of period 224.7
Other Current Liabilities [Member]  
Schedule of Activity in Contingent Consideration [Roll Forward]  
Balance at beginning of period 64.4
Payments 9.7
Reclassifications 10.7
Accretion expense 0.0
Fair value loss 0.0
Balance at end of period 65.4
Other long-term obligations  
Schedule of Activity in Contingent Consideration [Roll Forward]  
Balance at beginning of period 310.6
Payments 0.0
Reclassifications (10.7)
Accretion expense 5.7
Fair value loss 1.5
Balance at end of period $ 307.1